| Non-Small Cell Lung Carcinoma
Cyramza vs Hyrnuo
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Cyramza vs Hyrnuo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHyrnuo has a higher rate of injection site reactions vs Cyramza based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Hyrnuo but not Cyramza, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cyramza
Hyrnuo
At A Glance
IV infusion
Every 2 weeks
VEGFR2 antagonist
Oral
Twice daily
HER2 kinase inhibitor
Indications
- Gastric Adenocarcinoma
- Non-Small Cell Lung Carcinoma
- Metastasis from malignant neoplasm of colon and/or rectum
- Liver carcinoma
- Non-Small Cell Lung Carcinoma
Dosing
Gastric Adenocarcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent or in combination with weekly paclitaxel.
Non-Small Cell Lung Carcinoma (EGFR exon 19/21, first-line) 10 mg/kg every 2 weeks by IV infusion in combination with erlotinib.
Non-Small Cell Lung Carcinoma (post-platinum progression) 10 mg/kg by IV infusion on Day 1 of a 21-day cycle in combination with docetaxel.
Metastasis from malignant neoplasm of colon and/or rectum 8 mg/kg every 2 weeks by IV infusion prior to FOLFIRI.
Liver carcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent.
Non-Small Cell Lung Carcinoma 20 mg orally twice daily with food until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) Hypertension, fatigue/asthenia, neutropenia, diarrhea, epistaxis, peripheral edema, stomatitis, proteinuria, thrombocytopenia, decreased appetite, nausea.
Serious Febrile neutropenia, pneumonia, hemorrhage, gastrointestinal perforation, arterial thromboembolic events, impaired wound healing, posterior reversible encephalopathy syndrome, proteinuria including nephrotic syndrome, infusion-related reactions, sepsis.
Postmarketing Thrombotic microangiopathy, hemangioma, dysphonia, arterial aneurysms/dissections/rupture, heart failure.
Most common (>20%) Diarrhea, rash, paronychia, stomatitis, nausea
Serious Diarrhea, pneumonia, dyspnea, pleural effusion
Pharmacology
Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands VEGF-A, VEGF-C, and VEGF-D, inhibiting ligand-stimulated activation of VEGFR2 and thereby inhibiting endothelial cell proliferation, migration, and angiogenesis.
Sevabertinib is a reversible kinase inhibitor of HER2 (ERBB2) that also exhibits activity against EGFR; it inhibits HER2 phosphorylation and downstream signaling in cancer cells harboring HER2 alterations and demonstrates antitumor activity in NSCLC models with activating HER2 exon 20 mutations.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cyramza
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
Hyrnuo
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Cyramza
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Hyrnuo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Cyramza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Hyrnuo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cyramza.
No savings programs available for Hyrnuo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CyramzaView full Cyramza profile
HyrnuoView full Hyrnuo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.